| 证券代码 | TBIO.O |
| 证券名称 | Translate Bio Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2018-06-28 |
| 首发价格(元) | 13 USD |
| 首发数量(股) | 9350000 |
| 首发募资额(元) | 121,550,000.00 USD |
| 首发主承销商 | Citigroup Global Markets Inc.,Leerink Partners LLC,Evercore Grou |
| 货币单位 | USD |
| 公司名称 | Translate Bio, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 29 Hartwell Avenue, Lexington, Massachusetts, USA |
| 成立日期 | 2016-11-10 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.translate.bio |
| 电话 | +1 (617) 945-7361 |
| 传真 | - |
| 公司简介 | Translate Bio, Inc. is a leading messenger RNA, or mRNA, therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Using its proprietary mRNA therapeutic platform, or MRT platform, it creates mRNA that encodes functional proteins. It believes that the mRNA design, delivery and manufacturing capabilities of its MRT platform provide its with the most advanced platform for developing product candidates that deliver mRNA encoding functional proteins for therapeutic uses. |